Matinas BioPharma Holdings, Inc. MTNB
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is an infectious disease drug developer. Its lead program, MAT2203 (oral amphotericin B, LNC platform), is in Phase 2 for invasive aspergillosis in patients with limited treatment options (cryptococcal meningitis Phase 2 EnACT completed).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MAT2203 (oral amphotericin B) | invasive aspergillosis (planned single Phase 3 ORALTO; not started, paused pending partner or capital) | small molecule | Phase 2 |
| LNC platform oncology / oligonucleotide programs | oncology and inflammation | oligonucleotide-other | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.